Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by V.E.O. Ozougwu
Total Records ( 1 ) for V.E.O. Ozougwu
  V.E.O. Ozougwu and B.O. Akuba
  Background and Objective: Hydrolysis of carbohydrates to dextrin by pancreatic α-amylase activity which is further hydrolyzed into glucose by intestinal α-glucosidase enzyme causes elevation of blood glucose leading to postprandial hyperglycaemia. Inhibition of these enzymes is an important strategy in the management of diabetes mellitus. The aim of this study was to evaluate the effect of methanol extract of Desmodium velutinum leaves (MEDVL) on α-amylase in vitro and a possible corresponding anti-hyperglycaemic effect in vivo. Materials and Methods: The in vitro assay for inhibitory effect of MEDVL on α-amylase and α-glucosidase activities was performed according to standard protocols by reacting the enzymes and substrates with different concentrations (20-100 μg mL–1) of the extract in relation to acarbose while the enzyme kinetics (mode of Inhibition) assay for both enzymes were determined using the Lineweaver-Burk plot. The in vivo anti-hyperglycaemic activity of the extract in relation to acarbose was investigated after starch and sucrose load on alloxan induced hyperglycaemic rats. Results: The results revealed that MEDVL had a higher IC50 (88.2 and 83.5 μg mL–1) than acarbose (73.5 and 73.9 μg mL–1) for α-amylase and α-glucosidase, hence less potent than acarbose. The enzyme kinetics assay, the Lineweaver-Burke plot showed that MEDVL demonstrate a mixed non-competitive inhibition of α-amylase and uncompetitive inhibition of α-glucosidase activities compared with the control (acarbose) that it inhibits α-amylase in a competitive and α-glucosidase in a non-competitive manner. The in vivo anti-hyperglycaemic analyses revealed that the MEDVL caused significant reduction (p<0.05) in the postprandial blood glucose level, suppressed postprandial rise in blood glucose in rats within 2 h after starch and sucrose load. Conclusion: The MEDVL is a potent inhibitor for carbohydrate metabolizing enzymes which can be used in the management of type 2 diabetes mellitus.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility